Scholar Rock (NASDAQ:SRRK) General Counsel Sells $356,551.68 in Stock

Scholar Rock Holding Corporation (NASDAQ:SRRK) General Counsel Junlin Ho sold 8,016 shares of Scholar Rock stock in a transaction on Friday, January 16th. The stock was sold at an average price of $44.48, for a total value of $356,551.68. Following the sale, the general counsel owned 214,553 shares in the company, valued at $9,543,317.44. This trade represents a 3.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.

Scholar Rock Stock Performance

NASDAQ:SRRK traded up $1.31 during trading on Wednesday, reaching $46.05. The company’s stock had a trading volume of 1,173,163 shares, compared to its average volume of 836,796. Scholar Rock Holding Corporation has a 12 month low of $22.71 and a 12 month high of $48.28. The firm has a market cap of $4.70 billion, a price-to-earnings ratio of -14.62 and a beta of 0.63. The firm has a 50 day moving average of $43.23 and a 200-day moving average of $37.16. The company has a debt-to-equity ratio of 0.41, a quick ratio of 6.30 and a current ratio of 6.30.

Scholar Rock (NASDAQ:SRRK) last released its earnings results on Friday, November 14th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.02). During the same period in the prior year, the company posted ($0.66) earnings per share. Research analysts expect that Scholar Rock Holding Corporation will post -2.42 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Three Seasons Wealth LLC increased its position in shares of Scholar Rock by 2.1% during the fourth quarter. Three Seasons Wealth LLC now owns 10,968 shares of the company’s stock valued at $483,000 after buying an additional 222 shares during the period. Principal Financial Group Inc. grew its stake in Scholar Rock by 7.9% during the third quarter. Principal Financial Group Inc. now owns 6,214 shares of the company’s stock valued at $231,000 after acquiring an additional 456 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in Scholar Rock by 15.8% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,668 shares of the company’s stock worth $130,000 after acquiring an additional 500 shares during the period. California State Teachers Retirement System lifted its stake in Scholar Rock by 0.9% in the 2nd quarter. California State Teachers Retirement System now owns 62,372 shares of the company’s stock worth $2,209,000 after purchasing an additional 577 shares in the last quarter. Finally, Tema Etfs LLC boosted its holdings in Scholar Rock by 6.6% in the 4th quarter. Tema Etfs LLC now owns 9,899 shares of the company’s stock valued at $436,000 after purchasing an additional 616 shares during the period. Hedge funds and other institutional investors own 91.08% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on SRRK shares. Truist Financial decreased their price target on shares of Scholar Rock from $54.00 to $44.00 and set a “buy” rating for the company in a research note on Monday, October 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of Scholar Rock in a report on Wednesday, October 8th. Piper Sandler lowered their target price on Scholar Rock from $52.00 to $51.00 and set an “overweight” rating on the stock in a research note on Wednesday, September 24th. Citigroup initiated coverage on Scholar Rock in a research report on Friday, January 9th. They set a “buy” rating and a $55.00 price target on the stock. Finally, HC Wainwright decreased their price objective on Scholar Rock from $50.00 to $44.00 and set a “buy” rating for the company in a report on Tuesday, September 23rd. Four research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $50.14.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).